No Data
ImmuneOnco Biopharmaceuticals Seeks HK$230 Million in Placement Deal; Shares Fall 6%
Yiming Anke-B (01541.HK) plans to place a total of 33.15 million new shares listed in hong kong, raising a total of 0.234 billion HKD.
On November 21, Glonghui reported that Yiming Anke-B (01541.HK) announced that on November 21, 2024, the company entered into a placing agreement with china international capital corporation (acting as the placing agent). According to this agreement, the placing agent has agreed to act as the company's exclusive placing agent and will make every effort to encourage subscribers to purchase a total of 33.15 million new H shares at a placing price of HKD 7.05 per share, in accordance with the terms stated in the placing agreement and under the conditions contained in that agreement. The placing shares account for approximately 8.86% and 9.50% of the company’s issued share capital and total issued H shares, respectively, as of the date of this announcement.
Yiming Anke (01541.HK) IMM0306 clinical research is currently actively recruiting and observing.
Yiming Anke (01541.HK) announced that the Ib/IIa clinical trial of IMM0306 in combination with lenalidomide for the treatment of chronic lymphoma has recruited a total of 27 evaluable patients (25 patients with follicular lymphoma (FL) and two patients with marginal zone lymphoma (MZL)) as of October 26. As of October 26, the overall response rate (ORR) and complete response rate (CRR) for 25 evaluable R/R FL patients were 84% and 40% respectively, while the ORR for R/R MZL reached 100% in the two evaluable patients, indicating outstanding efficacy signals.
Yiming Pharmaceutical-B (01541.HK) announced positive clinical trial results for the combination of IMM0306 and lenalidomide in the treatment of chronic lymphocytic leukemia.
Gelonghui, November 18, 2023丨Yiming Anke-B (01541.HK) announced that the Phase Ib/IIa clinical trial for the treatment of chronic lymphoma with IMM0306 in combination with lenalidomide has recruited a total of 27 evaluable patients (25 patients with follicular lymphoma (FL) and two patients with marginal zone lymphoma (MZL)) as of October 26, 2024. The following figure illustrates the efficacy data for patients with recurrent or refractory (R/R) FL as of October 26, 2024: as of October 26, 2024, among 25 evaluable R/R FL patients, the overall response rate (
Express News | Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Yiming Anke-B (01541.HK) has initiated a Phase II clinical trial for the treatment of estrogen receptor-positive (ER+) advanced breast cancer after failure or recurrence of endocrine therapy.
November 13th, Yimengangke-B (01541.HK) announced that the company has initiated a Phase II clinical trial of IMM27M for estrogen receptor-positive (ER+) advanced breast cancer after endocrine therapy failure or recurrence, recruiting the first patient. In addition, the IMM27M Phase I dose escalation study was completed at the end of 2023, with the following results (as of August 6, 2024): In the Phase I trial, a total of eight evaluable ER+ advanced or metastatic breast cancer patients were recruited. Among them, two achieved partial responses (PR) and four patients had stable disease (SD), overall.
No Data
No Data